Enanta Pharma GAAP EPS of -1.07 beats by 0.38, revenue of 18M beats by 0.84M
ENTA Stock | USD 8.56 0.45 4.99% |
About 66% of Enanta Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Enanta Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Enanta Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Enanta Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Enanta |
Enanta Pharma beats expectations with Q3 earnings report, posting a GAAP EPS of -1.07 and revenue of 18M.
Read at seekingalpha.com
Enanta Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Enanta Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Enanta Pharmaceuticals Fundamental Analysis
We analyze Enanta Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Enanta Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Enanta Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enanta Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Enanta Pharmaceuticals Related Equities
DSGN | Design Therapeutics | 9.43 | ||||
INBX | Inhibrx | 3.97 | ||||
IPSC | Century Therapeutics | 3.85 | ||||
RVMD | Revolution Medicines | 1.97 | ||||
CGEM | Cullinan Oncology | 1.83 | ||||
GLUE | Monte Rosa | 1.65 | ||||
CRNX | Crinetics Pharmaceuticals | 1.21 | ||||
LYEL | Lyell Immunopharma | 1.10 | ||||
MRUS | Merus BV | 1.06 | ||||
EWTX | Edgewise Therapeutics | 0.31 | ||||
STOK | Stoke Therapeutics | 0.08 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
MLYS | Mineralys Therapeutics, | 1.42 | ||||
HOWL | Werewolf Therapeutics | 2.00 | ||||
KRON | Kronos Bio | 2.25 | ||||
CCCC | C4 Therapeutics | 4.34 |
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |